Real-world Study of Seladelpar for Primary Biliary Cirrhosis
Part of Digestive system clinical trials.
This study follows patients who are already taking seladelpar (a medication) for primary biliary cirrhosis—a liver disease where the immune system damages bile ducts. Researchers want to understand how well the medication works and how safe it is when used in everyday clinical practice outside of controlled trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with primary biliary cirrhosis (PBC) using standard diagnostic criteria
- You are currently being treated with seladelpar
- You are able and willing to provide written informed consent
- You have not participated in any other research trial testing seladelpar for PBC
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral drug called seladelpar for people with PBC who also have cirrhosis that is well-controlled. The goal is to see if it helps improve liver health and manage symptoms without causing serious side effects.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
This study tests a medication called seladelpar to see if it can help treat narrowed bile ducts (ischemic cholangiopathy) that can occur after a liver transplant. It may be an option for people who are otherwise stable and not dealing with other major health issues.
This trial is testing whether adding fenofibrate to the standard PBC medicine ursodeoxycholic acid helps people with primary biliary cholangitis. It's a real-world study, meaning it looks at how treatments work in everyday practice. You can join only if you have already completed an earlier fenofibrate study.
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Hear when a new Primary Bilary Cirrhosis (PBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.